Gain Therapeutics (GANX) Tax Provisions (2020 - 2026)
Gain Therapeutics (GANX) posted Tax Provisions of $104070.0 for Q2 2026, down 43.15% on a QoQ basis from $183066.0 in Q1 2026, and down 26.3% year-over-year from $141205.0 in Q2 2025.
Powered by 
Analysis
Gain Therapeutics (GANX) Tax Provisions (2020 - 2026) Analysis & Trends
Gain Therapeutics has reported Tax Provisions for 7 years, with the latest figure at $104070.0 in Q2 2026.
- On a quarterly basis, Tax Provisions fell 26.3% year-over-year to $104070.0 in Q2 2026; TTM through Jun 2026 was -$4.0 million, a 628.74% decrease from a year earlier, with the FY2025 full-year figure at -$4.1 million, down 855.01% from the prior year.
- Tax Provisions was $104070.0 for Q2 2026 at Gain Therapeutics, down from $183066.0 in the prior quarter.
- The five-year high for Tax Provisions was $549288.0 in Q3 2025, with the low at -$4.8 million in Q4 2025.
- Average Tax Provisions over 5 years is -$169794.3, with a median of $20665.0 recorded in 2023.
- The largest YoY upside for Tax Provisions was 11579.49% in 2025 against a maximum downside of 1059.71% in 2025.
- Over 5 years, Tax Provisions stood at $78105.0 in 2022, then slumped by 81.43% to $14502.0 in 2023, then surged by 3380.47% to $504738.0 in 2024, then tumbled by 1059.71% to -$4.8 million in 2025, then surged by 102.15% to $104070.0 in 2026.
- The last three Tax Provisions figures came in at $104070.0 (Q2 2026), $183066.0 (Q1 2026), and -$4.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | 104,070.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 104,070.00 |
| Mar 31, 2026 | 183,066.00 |
| Dec 31, 2025 | -4.84 Mn |
| Sep 30, 2025 | 549,288.00 |
| Jun 30, 2025 | 141,205.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 504,738.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 1,209.00 |
| Mar 31, 2024 | 19,874.00 |
| Dec 31, 2023 | 14,502.00 |
| Sep 30, 2023 | 21,456.00 |
| Jun 30, 2023 | 26,589.00 |
| Mar 31, 2023 | 16,728.00 |
| Dec 31, 2022 | 78,105.00 |
| Sep 30, 2022 | 4,048.00 |
| Jun 30, 2022 | 9,146.00 |
| Mar 31, 2022 | 1,677.00 |
| Dec 31, 2021 | -8,244.00 |
| Sep 30, 2021 | 5,114.00 |